Last reviewed · How we verify
Deflux
At a glance
| Generic name | Deflux |
|---|---|
| Also known as | Dextranomer/hyaluronic acid |
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cross-linked Hyaluronic Acid/dextranomer for the Treatment of Stress Urinary Incontinence (PHASE2)
- Study to Evaluate Solesta for Treatment of Fecal Incontinence (NA)
- Endoscopic Injection of Dextranomer/Hyaluronic Acid Versus Ureteral Reimplantation In Treatment of Vesicoureteral Reflux (NA)
- Minimally Invasive Closure of Umbilical Hernias (NA)
- Prospective Pediatric Vesicoureteral Reflux Surgery Database
- A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children (PHASE4)
- A Randomized, Controlled, Clinical Trial of Biofeedback and Anal Injections as First Treatment of Fecal Incontinence (PHASE1)
- Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deflux CI brief — competitive landscape report
- Deflux updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI